Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Consolidated Statements of Comprehensive Loss

v3.22.1
Consolidated Statements of Comprehensive Loss - CAD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Expenses      
 Amortization $ 17,882 $ 20,439 $ 19,900
 Consulting 724,272 102,880 46,561
 Directors’ fees 62,200
 General and administrative 176,099 9,516 17,344
 Investor relations 518,615 241,177 34,782
 Listing fees 236,801 52,138 42,495
 Professional fees 272,943 162,580 108,427
 Research and development 853,124 277,455 39,897
 Share-based payments 499,158 293,443 26,317
 Travel 2,339 8,460 36,076
 Wages and benefits 286,090 227,905 194,166
Loss before other items (3,649,523) (1,395,993) (565,965)
Accretion (846) (1,638)
Transaction costs on derivative warrant liability (1,623,680)
Fair value adjustment on derivative warrant liability 3,299,768
Foreign exchange gain (loss) 326,751 2,961 (26,397)
Impairment of intangible assets (64,562)
Interest and other expenses (5,598) (12,666) (35,576)
Forgiveness of debt 91,014
Recovery of provision for patent acquisition 95,490
Net loss and comprehensive loss for the year $ (1,652,282) $ (1,284,602) $ (629,576)
Basic and diluted loss per common share $ (0.17) $ (0.19) $ (0.12)
Weighted average number of common shares outstanding Basic and diluted $ 9,847,641 $ 6,664,025 $ 5,359,444